A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2007-2019

ABSTRACT

Non-small cell lung cancer (NSCLC) can be treated with drugs that kill tumour cells, stop them from dividing, or stop the growth of the blood supply that cancers need to grow and spread. Clinical research has shown that drugs that inhibit vascular endothelial growth factor receptor (VEGFR) or epidermal growth factor receptor (EGFR) signalling can increase overall survival in patients with advanced non-small cell lung cancer (NSCLC). Preclinical studies have shown that vandetanib (ZD6474) is an inhibitor of both VEGFR and EGFR signalling. Giving vandetanib may therefore inhibit the growth of cancer cells by blocking their blood supply and by stopping them from dividing. This lung cancer study is to investigate if adding vandetanib to Alimta (pemetrexed) is more effective than Alimta (pemetrexed) alone. Detailed Description This randomized phase III non-small cell lung cancer clinical trial is studying the effect of Alimta (pemetrexed) plus vandetanib to see how well the combination works compared to Alimta (pemetrexed) alone in patients who have previously been treated for non-small cell lung cancer (NSCLC). More... »

URL

https://clinicaltrials.gov/show/NCT00418886

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Non-small cell lung cancer (NSCLC) can be treated with drugs that kill tumour cells, stop them from dividing, or stop the growth of the blood supply that cancers need to grow and spread. Clinical research has shown that drugs that inhibit vascular endothelial growth factor receptor (VEGFR) or epidermal growth factor receptor (EGFR) signalling can increase overall survival in patients with advanced non-small cell lung cancer (NSCLC). Preclinical studies have shown that vandetanib (ZD6474) is an inhibitor of both VEGFR and EGFR signalling. Giving vandetanib may therefore inhibit the growth of cancer cells by blocking their blood supply and by stopping them from dividing. This lung cancer study is to investigate if adding vandetanib to Alimta (pemetrexed) is more effective than Alimta (pemetrexed) alone.\n\nDetailed Description\nThis randomized phase III non-small cell lung cancer clinical trial is studying the effect of Alimta (pemetrexed) plus vandetanib to see how well the combination works compared to Alimta (pemetrexed) alone in patients who have previously been treated for non-small cell lung cancer (NSCLC).", 
    "endDate": "2019-12-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT00418886", 
    "keywords": [
      "Phase III", 
      "parallel group", 
      "multi-centre study", 
      "Equidae", 
      "efficacy", 
      "safety", 
      "patient", 
      "NSCLC", 
      "Non-Small-Cell Lung Carcinoma", 
      "drug", 
      "tumor cell", 
      "stop", 
      "blood supply", 
      "Biomedical Research", 
      "vascular endothelial growth factor receptor", 
      "epidermal growth factor receptor", 
      "signaling", 
      "overall survival", 
      "preclinical study", 
      "vandetanib", 
      "inhibitor", 
      "cancer cell", 
      "cancer study", 
      "non small cell lung cancer"
    ], 
    "name": "A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA\u2122) in Combination With Pemetrexed (Alimta\u00ae) Versus Pemetrexed Alone in Patients With Locally-Advanced or Metastatic NSCLC", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT00418886"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00003.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.417555.7", 
        "type": "Organization"
      }
    ], 
    "startDate": "2007-01-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1200/jco.2010.29.5717", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013535496"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12885-015-1146-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014779199", 
          "https://doi.org/10.1186/s12885-015-1146-8"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT00418886"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00418886'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00418886'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00418886'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00418886'


 

This table displays all metadata directly associated to this object as RDF triples.

50 TRIPLES      16 PREDICATES      41 URIs      33 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT00418886 schema:about anzsrc-for:3142
2 schema:description Non-small cell lung cancer (NSCLC) can be treated with drugs that kill tumour cells, stop them from dividing, or stop the growth of the blood supply that cancers need to grow and spread. Clinical research has shown that drugs that inhibit vascular endothelial growth factor receptor (VEGFR) or epidermal growth factor receptor (EGFR) signalling can increase overall survival in patients with advanced non-small cell lung cancer (NSCLC). Preclinical studies have shown that vandetanib (ZD6474) is an inhibitor of both VEGFR and EGFR signalling. Giving vandetanib may therefore inhibit the growth of cancer cells by blocking their blood supply and by stopping them from dividing. This lung cancer study is to investigate if adding vandetanib to Alimta (pemetrexed) is more effective than Alimta (pemetrexed) alone. Detailed Description This randomized phase III non-small cell lung cancer clinical trial is studying the effect of Alimta (pemetrexed) plus vandetanib to see how well the combination works compared to Alimta (pemetrexed) alone in patients who have previously been treated for non-small cell lung cancer (NSCLC).
3 schema:endDate 2019-12-01T00:00:00Z
4 schema:keywords Biomedical Research
5 Equidae
6 NSCLC
7 Non-Small-Cell Lung Carcinoma
8 Phase III
9 blood supply
10 cancer cell
11 cancer study
12 drug
13 efficacy
14 epidermal growth factor receptor
15 inhibitor
16 multi-centre study
17 non small cell lung cancer
18 overall survival
19 parallel group
20 patient
21 preclinical study
22 safety
23 signaling
24 stop
25 tumor cell
26 vandetanib
27 vascular endothelial growth factor receptor
28 schema:name A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination With Pemetrexed (Alimta®) Versus Pemetrexed Alone in Patients With Locally-Advanced or Metastatic NSCLC
29 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00418886
30 schema:sdDatePublished 2019-03-07T15:22
31 schema:sdLicense https://scigraph.springernature.com/explorer/license/
32 schema:sdPublisher Neb1dba5b62ad400184d473db726bfdb0
33 schema:sponsor https://www.grid.ac/institutes/grid.417555.7
34 schema:startDate 2007-01-01T00:00:00Z
35 schema:subjectOf sg:pub.10.1186/s12885-015-1146-8
36 https://doi.org/10.1200/jco.2010.29.5717
37 schema:url https://clinicaltrials.gov/show/NCT00418886
38 sgo:license sg:explorer/license/
39 sgo:sdDataset clinical_trials
40 rdf:type schema:MedicalStudy
41 Neb1dba5b62ad400184d473db726bfdb0 schema:name Springer Nature - SN SciGraph project
42 rdf:type schema:Organization
43 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
44 rdf:type schema:DefinedTerm
45 sg:pub.10.1186/s12885-015-1146-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014779199
46 https://doi.org/10.1186/s12885-015-1146-8
47 rdf:type schema:CreativeWork
48 https://doi.org/10.1200/jco.2010.29.5717 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013535496
49 rdf:type schema:CreativeWork
50 https://www.grid.ac/institutes/grid.417555.7 schema:Organization
 




Preview window. Press ESC to close (or click here)


...